Total Payments
$135,607
2024 Payments
$131,454
Companies
32
Transactions
196
Medicare Patients
4,496
Medicare Billing
$1.6M
Payment Breakdown by Category
Research$130,163 (96.0%)
Food & Beverage$5,193 (3.8%)
Education$250.87 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $130,163 | 1 | 96.0% |
| Food and Beverage | $5,193 | 191 | 3.8% |
| Education | $250.87 | 4 | 0.2% |
Payments by Type
Research
$130,163
1 transactions
General
$5,444
195 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $130,163 | 1 | $0 (2024) |
| Otsuka America Pharmaceutical, Inc. | $540.68 | 19 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $535.41 | 24 | $0 (2024) |
| Relypsa, Inc. | $376.87 | 15 | $0 (2020) |
| Amgen Inc. | $360.76 | 13 | $0 (2024) |
| OPKO Pharmaceuticals, LLC | $360.58 | 21 | $0 (2024) |
| Mallinckrodt Enterprises LLC | $328.40 | 9 | $0 (2019) |
| Mallinckrodt Hospital Products Inc. | $309.03 | 11 | $0 (2024) |
| Aurinia Pharma U.S., Inc. | $250.85 | 7 | $0 (2024) |
| Fresenius USA Marketing, Inc. | $235.61 | 10 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $131,454 | 54 | Eli Lilly and Company ($130,163) |
| 2023 | $516.33 | 23 | Otsuka America Pharmaceutical, Inc. ($108.80) |
| 2022 | $560.44 | 25 | AstraZeneca Pharmaceuticals LP ($199.62) |
| 2021 | $730.70 | 28 | Mallinckrodt Hospital Products Inc. ($195.97) |
| 2020 | $501.82 | 14 | Silk Road Medical, Inc. ($182.66) |
| 2019 | $571.48 | 15 | OPKO Pharmaceuticals, LLC ($138.31) |
| 2018 | $619.11 | 16 | Mallinckrodt LLC ($195.68) |
| 2017 | $653.23 | 21 | Relypsa, Inc. ($200.80) |
All Payment Transactions
196 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $20.05 | General |
| 12/20/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $17.35 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 12/19/2024 | Travere Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $19.49 | General |
| 12/13/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $13.43 | General |
| Category: Cardio-renal | ||||||
| 11/25/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $24.92 | General |
| Category: Inflammation | ||||||
| 11/21/2024 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $27.23 | General |
| Category: NEPHROLOGY | ||||||
| 11/20/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $130,163.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE | ||||||
| 10/28/2024 | Fresenius USA Marketing, Inc. | Velphoro (Drug) | Food and Beverage | In-kind items and services | $17.99 | General |
| Category: Phosphate binder for ESRD | ||||||
| 10/22/2024 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $13.86 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/14/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $20.11 | General |
| Category: Inflammation/Rare Disease | ||||||
| 10/09/2024 | OPKO Pharmaceuticals, LLC | RAYALDEE (Drug) | Food and Beverage | In-kind items and services | $18.38 | General |
| Category: NEPHROLOGY | ||||||
| 10/07/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $24.31 | General |
| 10/03/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $29.28 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/30/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $21.27 | General |
| Category: IMMUNOLOGY | ||||||
| 09/27/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $16.30 | General |
| Category: Diabetes | ||||||
| 09/26/2024 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $24.67 | General |
| Category: NEPHROLOGY | ||||||
| 09/23/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $23.64 | General |
| Category: Cardio-renal | ||||||
| 09/19/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $20.35 | General |
| Category: GASTROENTEROLOGY | ||||||
| 09/06/2024 | Xeris Pharmaceuticals, Inc. | KEVEYIS (Drug) | Food and Beverage | In-kind items and services | $24.77 | General |
| Category: Carbonic anhydrase inhibitor | ||||||
| 08/30/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $18.56 | General |
| Category: Inflammation/Rare Disease | ||||||
| 08/22/2024 | CALLIDITAS THERAPEUTICS US INC. | TARPEYO (Drug) | Food and Beverage | In-kind items and services | $19.00 | General |
| Category: Nephrology | ||||||
| 08/20/2024 | AKEBIA THERAPEUTICS INC | — | Food and Beverage | In-kind items and services | $103.39 | General |
| 08/16/2024 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $2.86 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 08/15/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $23.70 | General |
| 08/15/2024 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $22.86 | General |
| Category: Cardiovascular and Metabolism | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE | Eli Lilly and Company | $130,163 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 1,131 | 3,513 | $678,200 | $372,909 |
| 2022 | 11 | 1,146 | 3,656 | $727,815 | $392,624 |
| 2021 | 11 | 1,046 | 3,397 | $712,480 | $392,993 |
| 2020 | 12 | 1,173 | 3,905 | $848,710 | $415,146 |
Total Patients
4,496
Total Services
14,471
Medicare Billing
$1.6M
Procedure Codes
47
All Medicare Procedures & Services
47 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2023 | 63 | 510 | $255,000 | $137,958 | 54.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 353 | 1,890 | $206,360 | $114,623 | 55.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 203 | 442 | $77,345 | $42,602 | 55.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 161 | 173 | $42,385 | $23,018 | 54.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 102 | 203 | $29,435 | $18,642 | 63.3% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2023 | 31 | 49 | $17,150 | $11,055 | 64.5% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 88 | 95 | $16,600 | $9,414 | 56.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 39 | 39 | $8,385 | $4,825 | 57.5% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2023 | 32 | 50 | $11,000 | $2,753 | 25.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 14 | 14 | $3,780 | $2,347 | 62.1% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 13 | 13 | $5,200 | $2,149 | 41.3% |
| 90962 | Dialysis services, 1 physician visit per month (20 years or older) | Office | 2023 | 12 | 13 | $3,250 | $2,019 | 62.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 20 | 22 | $2,310 | $1,504 | 65.1% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2022 | 75 | 590 | $295,000 | $163,590 | 55.5% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 375 | 1,941 | $213,030 | $105,886 | 49.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 199 | 450 | $78,750 | $42,543 | 54.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 161 | 170 | $41,650 | $25,786 | 61.9% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 114 | 223 | $32,335 | $17,465 | 54.0% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2022 | 38 | 64 | $22,400 | $14,784 | 66.0% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 88 | 98 | $17,150 | $10,110 | 59.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 34 | 34 | $7,310 | $4,244 | 58.1% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2022 | 33 | 55 | $12,100 | $3,083 | 25.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 17 | 17 | $4,590 | $2,898 | 63.1% |
| 90962 | Dialysis services, 1 physician visit per month (20 years or older) | Office | 2022 | 12 | 14 | $3,500 | $2,235 | 63.9% |
| 90960 | Dialysis services (4 or more physician visits per month), patient 20 years of age and older | Office | 2021 | 85 | 643 | $321,500 | $181,918 | 56.6% |
About Dr. Ritesh Mathur, M.D
Dr. Ritesh Mathur, M.D is a Nephrology healthcare provider based in Sugar Land, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/26/2006. The National Provider Identifier (NPI) number assigned to this provider is 1407802796.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ritesh Mathur, M.D has received a total of $135,607 in payments from pharmaceutical and medical device companies, with $131,454 received in 2024. These payments were reported across 196 transactions from 32 companies. The most common payment nature is "" ($130,163).
As a Medicare-enrolled provider, Mathur has provided services to 4,496 Medicare beneficiaries, totaling 14,471 services with total Medicare billing of $1.6M. Data is available for 4 years (2020–2023), covering 47 distinct procedure/service records.
Ad
Practice Information
- Specialty Nephrology
- Location Sugar Land, TX
- Active Since 05/26/2006
- Last Updated 07/23/2014
- Taxonomy Code 207RN0300X
- Entity Type Individual
- NPI Number 1407802796
Products in Payments
- ACTHAR (Biological) $637.43
- JYNARQUE (Drug) $509.28
- Veltassa (Drug) $469.08
- FARXIGA (Drug) $319.56
- KRYSTEXXA (Biological) $263.47
- LUPKYNIS (Drug) $250.85
- Velphoro (Drug) $235.61
- LOKELMA (Drug) $215.85
- Rayaldee (Drug) $196.14
- ENROUTE Transcarotid Neuroprotection System (Device) $182.66
- RAYALDEE (Drug) $164.44
- BENLYSTA (Biological) $142.10
- TARPEYO (Drug) $139.04
- EkoSonic (Device) $134.91
- SOLIRIS (Drug) $129.90
- Endurant (Device) $125.69
- EKOSONIC (Device) $124.99
- Parsabiv (Biological) $121.45
- Kerendia (Drug) $109.63
- Parsabiv (Drug) $76.16
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Nephrology Doctors in Sugar Land
Jingyin Yan, M.d., Ph.d, M.D., PH.D
Nephrology — Payments: $22,056
Nephrology $22,056
Dr. Ankita Gandhir, M.d, M.D
Nephrology — Payments: $2,756
Nephrology $2,756
Mrs. Humaira Chaudhary, M.d, M.D
Nephrology — Payments: $2,433
Nephrology $2,433
Shancy Jacob, D.o, D.O
Nephrology — Payments: $195.49
Nephrology $195.49
Kanwarpreet Baweja, Md, MD
Nephrology — Payments: $120.37
Nephrology $120.37